dacarbazine

P3, N=360, Recruiting, Immatics US, Inc. | N=96 --> 360

P3, N=96, Recruiting, Immatics US, Inc.

To mitigate pulmonary and myelotoxicity risks, he received a modified regimen of brentuximab vedotin (BV) combined with adriamycin, vinblastine, and dacarbazine (BV-AVD), with full omission of bleomycin. It underscores the critical need for individualized therapy in patients with DC and supports careful consideration of radiation omission to reduce secondary malignancy risk. These findings provide a potential therapeutic framework for managing Hodgkin lymphoma in patients with DC.

P3, N=994, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Mar 2027

Taken together, dacarbazine and the miR-204-5p mimic favor the dissemination of B16 melanoma cells in the lungs, which may support further metastatic development. Although miR-204-5p has been described as a tumor-suppressive microRNA in melanoma, the application of a synthetic mimic to overexpress it in distant organs promoted tumor cell dissemination.

Notably, COS-2 not only enhanced the anti-tumor efficacy of DTIC but also alleviated its side effects. The combination therapy with COS and DTIC exhibited a synergistic effect and may be a promising therapeutic strategy for melanoma.

Interestingly, some of these patients may derive meaningful benefit from cytotoxic chemotherapy. We present the report of a case of a 63-year-old lady with BRAF wild type, locally advanced mucosal melanoma who demonstrated disease progression on combination immunotherapy with Ipilimumab and nivolumab. She subsequently achieved an exceptional and durable radiological and clinical response to chemotherapy with cisplatin and dacarbazine. This case highlights that, despite advances in personalized medicine and immunotherapy, conventional chemotherapy may still represent a valuable therapeutic option in selected patients, particularly in the refractory setting.

P3, N=2921, Completed, University of Giessen | Active, not recruiting --> Completed | N=2200 --> 2921 | Trial completion date: Sep 2026 --> Oct 2025

After receiving six cycles of brentuximab+doxorubicin, vinblastine, and dacarbazine (A+AVD) therapy at our Department of Hematology (University of Debrecen), the patient achieved complete metabolic remission (CMR) and remains in good condition. HL-RT in CLL is relatively rare and generally associated with poorer outcomes, though it is typically more favorable than DLBCL-RT. In this case report, we highlight not only an uncommon anatomical location of HL-RT but also the absence of typical predisposing factors, such as a TP53 mutation, unmutated immunoglobulin heavy chain (IGHV) status, or a lack of 13q deletion.

P2, N=378, Completed, Immunocore Ltd | Active, not recruiting --> Completed

P2, N=92, Recruiting, Suzhou BlueHorse Therapeutics Co., Ltd. | Not yet recruiting --> Recruiting

P3, N=1334, Completed, Takeda | Active, not recruiting --> Completed